Aedivir

A research based specialty pharmaceutical company focused on infectious diseases

Q1 2012 Conference Call 10 May 10.00 AM (CET)



Presenting Team



Maris Hartmanis, CEO Charlotte Edenius, EVP R&D Bertil Samuelsson, Chief Scientific Advisor Rein Piir, EVP Corporate Affairs & IR





Summary of first quarter 2012

Maris Hartmanis, CEO



Strong momentum in our operations

- A phase II interferon free combination trial was initiated with TMC435 and Gilead's GS7977, with and without ribavirin
- Additional phase III trials were initiated with TMC435, including the large and very hard to treat patient group of previous null responders and patients with HCV, genotype 4
- Our internal proprietary, unpartnered, Hepatitis C projects are rapidly moving towards the CD stage
- GSK began the OTC launch of Xerclear® in Europe under the Zoviduo and Zovirax Duo brands
- An application to start phase I trials on Cathepsin K for treatment of skeletal disorders was filed with the European regulatory authority
- Medivir continues to have a solid financial position. Cash and cash equivalents amounted to SEK 485.6 (645.7) m at the end of the period



Post balance sheet events

- The clinical collaboration between our partner Janssen and Bristol-Myers Squibb (BMS) regarding TMC435 and daclatasvir was extended. In addition to interferon and ribavirin-free combination trials on TMC435 in phase II, this collaboration now also covers a phase III program
- The partnership with BMS also involves an evaluation of TMC435 in interferon and ribavirin-free combination trials with BMS's nucleotide inhibitor BMS-986094 (formerly INX-189)
- Medivir's partner Janssen has created a new subsidiary, Janssen Therapeutics EMEA, with a mission to launch TMC435 in Europe, the Middle East and Africa
- Strong final phase II data on TMC435 on hard to treat hepatitis C patients were presented at the EASL meeting



Q1 2012 Group level financial performance - stable sales development without one-off payments

CONSOLIDATED INCOME STATEMENT	2012	2011	2011
SUMMARY, (SEK m)	Jan-Mar	Jan-Mar	Jan-Dec
Net sales	137.9	121.6	698.6
Cost of goods sold	-97.0	-0.1	-240.6
Gross profit/loss	40.9	121.5	458.0
Selling expenses	-16.7	-2.1	-95.2
Administrative expenses	-15.1	-7.6	-47.2
Research and development costs	-46.7	-57.4	-184.1
Other operating income/expenses	-0.7	-4.3	-19.7
Operating profit/loss	-38.3	50.1	111.9
Net financial income/expense	0.8	2.8	-0.7
Profit/loss after financial items	-37.5	52.9	111.2
Тах	-0.2	0.0	2.5
Net profit/loss	-37.7	52.9	113.8




Q1 2012 financial performance at segment level - Margins remain at good levels in the first quarter

Net sales split	2012	2011	2011
_(SEK m)	Jan-Mar	Jan-Mar	Jan-Dec
Outlicensing and partnership agreements			
One-off payments	-	121.3	401.2
Pharmaceutical sales	46.3	0.2	111.2
Parallel imports	91.6	-	185.9
Other services	0.0	0.1	0.3
Total	137.9	121.6	698.6
Pharmaceuticals segment	2012	2011	2011
_(SEK m)	Jan-Mar	Jan-Mar	Jan-Dec
Net sales	46.3	121.6	512.7
EBITDA	-34.1	51.9	137.6
EBITDA %	-73.7%	42.7%	26.8%
Parallel Import segment	2012	2011	2011
(SEK m)	Jan-Mar	Jan-Mar	Jan-Dec
Net sales	91.6	-	185.9
	4.2	-	-2.3
EBITDA %	4.6%	-	-1.2%

. . . .



Strong platform for a leading position in hepatitis C







Strongly committed to innovation driven R&D


Charlotte Edenius, EVP R&D



Building on a longstanding protease inhibitor development experience

MIV-711 Cathepsin K inhibitor towards clinical trials

- Osteoarthritis, osteoporosis and metastatic bone disease
- Candidate drug selected, MIV-711
- Anticipated low QD dosage in man
- Regulatory safety documentation finalized and clinical trial application submitted



Cathepsin K inhibitor program to start Phase I in Q2 2012



Strong commitment in hepatitis C – four major programs on-going

Protease inhibitor – TMC-435

•Investigational, one pill, once daily, oral HCV protease inhibitor

•Potent antiviral activity in patients infected with HCV genotype 1

- •Favorable safety profile
- •Currently in Phase III clinical development

Nucleotide polymerase inhibitor

- Liver targeted nucleotide polymerase inhibitor program
- Candidate Drug selected and IND preparatory activities on-going

Nucleotide polymerase inhibitor

- Properties similar to the most advanced clinical nucleotides
- Both purines and pyrimidines with high potencies in the replicon assay
- High triphosphate levels and long triphosphate t1/2 in human hepatocytes
- Aiming for Candidate Drug selection in Q4, 2012

NS5A inhibitor

- A next generation NS5A inhibitor with high barrier to resistance
- Preclinical optimization phase





Internal unpartnered projects

TMC435, triple combination therapy with PegINF/RBV

- summary phase IIb data

Best-in-class potential based on Phase II data

• Safe and efficacious with excellent tolerability (150 mg, q.d., 12 w)

Study	Number of patients	Patient population	SVR24	
PILLAR	386	Treatment naive	81 - 86%	
DRAGON	92	Treatment naive (Japan)	82%	Robust clinical
ASPIRE	462	Relapsers	85%	efficacy data
		Partial responders	75%	
		Null responders	51%	

Efficacious in broad HCV patient populations


- Genotype 1
- Treatment naïve and treatment experienced patients
- Cirrhotic and non-cirrhotic patients

Large safety data base with approximately 1800 patients treated today



ASPIRE study:

A Phase IIb, randomised, double-blind clinical trial in treatment experienced HCV genotype 1 infected patients (n=462)




TMC435 either 100 or 150 mg QD

Primary endpoint: SVR24



ASPIRE study: proportion of patients achieving SVR24 by prior response




62 % of patients (287/462) had advanced liver disease (Metavir F2-F4)



*Dose groups (treatment duration) combined;

ASPIRE study: proportion of patients achieving SVR24 by prior response




Metavir: F0-F2



*Dose groups (treatment duration) combined;

ASPIRE study: proportion of patients achieving SVR24 by prior response

Cirrhotics (F4)





*Dose groups (treatment duration) combined;

ASPIRE study: adverse events

Note: mean PegIFN/RBV exposure longer for patients in TMC435 groups (41 weeks) compared with placebo group (28 weeks)

	TMC435 150 mg* n=199	Pbo PR48 n=66	
AEs leading to TMC435/Pbo discontinuation, %	9	5	
Serious adverse events, %	10	6	
Grade 3-4 AEs	36	26	
AEs most frequently reported inTMC435 groups (X	>25% of patients), 9	%	
Headache	40	36	
Fatigue	41	44	
Influenza-like illness	24	20	
Pruritus	35	17	
Neutropenia	28	17	
AEs of interest (regardless of severity or causality	y), %		
Hepatobiliary disorders	10	5	
Rash (any type) [†]	30	18	
Rash (any type), Grade 3	0.5	0	
Photosensitivity AEs	6	2	

Once-daily TMC435 was well tolerated in this population



*Dose groups combined; [†]Combines all types of reported rash; AE, adverse event; Pbo, placebo; PR, peginterferon α-2a + ribavirin

TMC 435 – triple combination summary

- Potent \rightarrow low dose (150mg), one tablet once daily, 12 weeks duration
- Safe and well tolerated
 - Close to 1800 patients have completed TMC435 treatments showing it to be safe and well tolerated important for compliance once on the market
- As demonstrated in three large phase IIb trials highly efficacious in;
 - G1a and G1b
 - treatment naïve and treatment experienced
 - cirrhotic and non-cirrhotic patients,
 - regardless of IP-10 level or *IL28B* genotype
- Long patent life, IP extending to 2026 and 2028

TMC-435: Best-in-class properties in triple combination standard of care treatment (to be filed H1 2013)



TMC435, broad clinical development program in HCV genotype 1 & 4 infected patients

Phase III

QUEST 1 treatment-naïve patients; n=375

QUEST 2 treatment-naïve patients; n=375

PROMISE (C3007) prior relapsed patients; n=375

Japan phase III program naïve and experienced patients; n=417 (four studies)

C3001 prior partial and null responders vs telepravir; n=744

C3011 naïve and experienced patients; n=100 open label in **G4** patients

IFN free combinations

TMC435 and GS-7977, a nucleotide NS5B inhibitor. 12/24 weeks, +/- ribavirin, null responders; +/- cirrhotics, n=180

On-going

TMC435 and daclatasvir

(BMS-790052), an NS5A inhibitor. 12/24 weeks, +/- ribavirin in G1 null responder and interferon intolerant patients

Planned to start H1-2012

TMC435 and BMS-986094 (INX-189) Clinical evaluation will start with a DDI study

Regulatory filings in first half of 2013 in US, EU and Japan






Hepatitis C – TMC435 treatment evolution INF-free combinations

Bertil Samuelsson, CSA



Evolution of HCV therapy in genotype 1 infection





Evolution of HCV therapy

DAA combinations, INF-free or INF /RBV-free, are being evaluated in phase II clinical trials

Lessons learned from 1-3 DAA combinations (+/- ribavirin)

- Proof-Of-Concept achieved
- Cirrhotic patients are either not being evaluated or display poor cure rates. These patients are the most difficult to treat and make up a substantial portion on the currently available patient pool
- SVR36 might be needed to capture real-life relapse rates in an IFN-free setting
- Very small patient groups in experimental trial designs

Ribavirin will not be part of future HCV combinations

- Ribavirin has severe side effects and safety issues
- Can cause severe adverse events in patients, e.g. hemolytic anemia, teratogenicity, cough, dyspnea, rash, pruritus, insomnia and anorexia. It is a powerful mutagenic agent and is contraindicated in pregnant women and patients with hemoglobinopathies

Phase III INF-free or INF /RBV-free trials have not yet started in HCV G1 patients



Evolution of HCV therapy

Goals - next generation standard of care treatments

- Combination of only two potent DAAs
 - Potential to meet cost and reimbursement challenges of the future
- Compelling efficacy, strong safety and minimal side effects
- 12 weeks treatment duration
- Fixed dose combination, once daily



Patient responses to treatment – a complex picture

- Genotype/subtype
- Liver disease, F4-F0
- Population
- IL28B at baseline
- Patient characteristics
 - Treatment experienced
 - Treatment naïves

N	/lost dif	ficult to tre	eat	Highest treatment responses	• • \
	G1a	G1b	G4/6	G3 G2	
	F4 (cirrhotic) F3		3	Non-cirrhotic (F2, F1 & F0)	
ĺ	Blacks	5	Hispanic	Caucasian	
	TT		СТ	сс	
ļ					
	null re	esponder	partial responder	relapser	ļ
l				treatment naïve	•

Treatment experienced patients (Metavir score)	% F4	% F3
TMC435 ASPIRE	18	19

TM435 deliver high cure rates also in the most difficult to treat, including cirrhotic patients (as shown in three large phase IIb trials)



IFN-free combinations - proof-of-concept achieved

One DAA + ribavirin

- GS-7977 + RBV

Cirrhotic patients NO

o SVR4 11%, 12 weeks in G1 null responders (n=9) ELECTRON trial

o SVR4 88%, 12 weeks, G1 treatment naïves (n=25), ELECTRON trial

- GS-7977 + RBV

Cirrhotic patients Yes

SVR4 53% (10/19), 12 weeks, G1 treatment naïves (including 20% cirrhotic patients) (n=19), QUANTUM trial

One nucleotide DAA + RBV - likely suboptimal combination



IFN + RBV-free combinations – first proof-of-concept achieved

Two DAAs only

- BMS daclatasvir + asunaprevir

Cirrhotic patients NO

- o 90% SVR12, 24 weeks, G1b null responders (Japan), patients, n= 21
- o 64% SVR12, 24 weeks, G1b IFN ineligible or intolerant (Japan), patients, n=22
- BMS daclatasvir + asunaprevir

Cirrhotic patients NO

- o 36% SVR12, 24 weeks, G1 null responders (64% RVR), n=11
- BMS daclatasvir + GS-7977

Cirrhotic patients NO

 100% SVR4 (SVR12 considered as cure rate), 24 weeks , (n=29), G1 treatment naïve patients



IFN-free combinations - proof-of-concept achieved

Two DAAs + ribavirin

- BI-201335 + BI-207127 + RBV
 - SVR12 68%, 28 weeks, G1 treatment naïve patients (including 10% cirrhotic patients) (SOUND-C2)
 - ✓ Note. Markedly lower SVR rate (39%) in RBV-free arm and in G1a patients and in non-CC IL28B genotype.

- ABT-450 + ritonavir + ABT-333 + ribavirin

o SVR12 93%(n=14); 95%(n=19), 12 weeks, G1 treatment naïve non-cirrhotic patients

- SVR12 47%, (n=17), 12 weeks, non-responders (6 null & 11 partial resp.), non-cirrhotic patients
- ABT-450 + ritonavir + ABT-072 + ribavirin

o 82% SVR36, 12 weeks, G1 treatment naïve non-cirrhotic patients, IL28B CC genotype

A protease inhibitor present in all these combinations



Cirrhotic patients Yes



Cirrhotic patients NO

Cirrhotic patients NO

TMC435 – interferon free combinations

Two DAAs +/- ribavirin

-TMC435 and GS-7977 (nucleotide NS5B inhibitor)

- o genotype 1 prior null responders, non-cirrhotic and cirrhotic patients, n=180
- o 12 and 24 weeks treatment durations, +/- RBV
- o On-going

-TMC435 and daclatasvir (NS5A inhibitor)

- o genotype 1 null responder and interferon intolerant patients
- o 12 and 24 weeks treatment durations, +/- RBV
- o Planned to start H1-2012

-TMC435 and BMS-986094 (former INX-189; a nucleotide NS5B inhibitor)

o Clinical evaluation will start with a DDI study

TMC435, a best in class PI, developed in IFN-free therapies



Cirrhotic patients Yes

Cirrhotic patients Yes

TMC435 IFN–free combinations

- TMC435 tripple therapy is today the only therapy that has shown to deliver high cure rates for the most difficult-to-treat cirrhotic patients in both treatment naïve and treatment experienced patients
- In the TMC435 treatment experienced ASPIRE trial the subgroups Null Responders, Partial Responders and Relapser patients achieved viral cure rates (SVR24) of 31%, 82% and 73% respectively vs 0% in all the INF/RBV control groups
- The new IFN-free combinations have so far only evaluated small groups of more easyto-treat non-fibrotic patients. In cases where fibrotic patients have been included the SVR rates drops dramatically
- The current TMC435 triple therapy offer an HCV cure for cirrhotic patients and future INF-free TMC435 combinations will also offer a cure for cirrhotic patients as well as for the treatment naïve patient and non-cirrhotic treatment experienced patient populations.



Expected key news flow highlights

- ✓ Q1-12 DAA phase II combination study with TMC435 and GS-7977 started
- ✓ Q1-12 OTC launch of Xerclear® (ZoviDuo) in Europe by GSK
- ✓ Q1-12 Start of Phase III trials with TMC435 + standard of care in prior null and partial responder patients vs telaprevir.
- ✓ Q2-12 Expanded agreement signed on TMC435 and daclatasvir (BMS-790052) collaboration
- ✓ Q2-12 TMC435 and BMS-986094 (formerly INX-189), two direct-acting antivirals in combination, will be evaluated in clinical trials
- ✓ Q2-12 EASL ASPIRE full SVR24 data
- ✓ Q2-12 Janssen creates new division to launch TMC435 in EMEA
- Q2-12 Start of DAA phase II combination study with TMC435 and daclatasvir
- Q2-12 Start of Phase I clinical trials with MIV-711 (cathepsin K inhibitor)
- Q4-12 Potential CD selection in our internal Nucleotide NS5B inhibitor program
- Q4-12 EoT-data from Cohort 1 with TMC435 and GS7977 DAA phase II study
- Q4-12 Potential CD selection in Cathepsin S (Neuropathic pain) program
- Q4-12 Goal to start phase 1 trials with Medivir/Janssen Nucleotide NS5B inhibitor
- Q4-12 Top line results from phase III trials with TMC435 (Quest 1+2 and Promise)

